Qiagen shares rallied 16.6% in Wednesday’s session, driven by a 45% surge in volume compared to the 30-day average of 5.8 million shares. Investors responded to stronger-than-expected order growth in the molecular diagnostics segment, which saw revenues climb 12% year-over-year in the first quarter. Analyst revisions have been mixed: while three firms raised full-year EPS forecasts by an average of 4 cents following the shipment data, two others trimmed estimates by 2 cents after noting supply-chain headwinds. Despite the strong session, implied volatility in options remains elevated at 28%, suggesting traders are pricing in continued swings rather than a sustained uptrend.

According to Bloomberg, Qiagen has engaged advisory banks to explore a strategic review process that could include a full or partial sale of the diagnostics business. Sources indicate that private equity groups and a leading life-sciences conglomerate have expressed preliminary interest, valuing the diagnostics unit at approximately €4.2 billion. The board is expected to evaluate final bids by early July and weigh the sale against organic investment in next-generation PCR platforms. Any transaction could reshape Qiagen’s capital allocation, potentially boosting free cash flow by an estimated €150 million annually if proceeds are redeployed into high-margin genomics services.